Global Glioblastoma Market: Overview
Glioblastoma also known as glioblastoma multiforme (GBM) is one of the most aggressive and most lethal brain disease that is currently taking many lives. The disease is responsible for more than 20% of total deaths that are caused by brain tumor. The life expectancy of the patient suffering from this disease is less than 14 months and the death is as painful as it can be. To reduce the number of deaths, researchers and pharmaceutical companies are developing drugs that can increase the life expectancy of the patients. Moreover, there are several developments that are done in the field of surgeries that can remove the tumor caused by glioblastoma multiforme (GBM). As a result of these developments, the global glioblastoma market is expected to witness a robust growth in the forecast period of 2019 to 2027.
A report by Transparency Market Research provides complete analysis of the global glioblastoma market for the period of 2019 to 2027. The report offers in-depth analysis of market allowing the readers to have better understanding of the dynamics of global glioblastoma market. It covers areas such as developments, challenges, opportunities and trends of the global glioblastoma market from 2019 to 2027.
Get an Idea about the Offerings of Our Glioblastoma Market Report from this Brochure
Global Glioblastoma Market: Notable Developments and Competitive Landscape
The global glioblastoma market is highly competitive along with being largely fragmented. This because, there are several players that dominates the dynamics of the global glioblastoma market from 2019 to 2027. To overcome this competition, businesses are implementing certain strategies that can help them achieve a sustainable future in the market. The players are resorting to steps such as mergers, partnerships and acquisitions to accommodate essential resources for a better future in global glioblastoma market.
- In 2019, Merck acquired Peloton Therapeutics, Inc., which is a privately owned clinical-stage biotherapeutical company. With this acquisition Merck gained a stronghold in division of small molecule development for treatment of hypoxia-inducible factor-2α (HIF-2α) in parents suffering from brain cancer. The acquisition allowed the company to enhance its portfolio of cancer treatment strengthening its position in the global glioblastoma market.
Also, some of the companies are filing patents to institutes such as FDA and European Commission for drug development. This strategy allow the players to acquire an edge over their rivals.
- In 2018, Amgen and Allergan PLC acquired the approval from European Commission to for marketing and promotion authorization of MVASI for glioblastoma treatment.
Expanding Operations in Future? To Get the Perfect Launch Ask for a Custom Glioblastoma Market Report
Global Glioblastoma Market: Key Drivers
Demand for New and Effective Drugs
According to a study by National Centre for Biotechnology Information or NCBI in 2019, the rate of growth in the cases of glioblastoma was escalated to 3.19 per 100,000 in 2017. This is an alarming growth rate since the death rate due to this disease has grown exponentially. This growth calls for therapies and drugs that reduce the number of deaths of the sufferers and increase their life expectancy. The growing demand for such drugs is the major factor driving the growth of global glioblastoma market in the forecast period of 2019 to 2027.
Improving Healthcare Infrastructure
Governments are hell-bound to find a cure for glioblastoma. For this, they are investing a massive amount in development of therapeutic centers, hospitals and diagnostic centers. Also, governments are investing their resources in development and implementation of new technologies that can boost drug development for glioblastoma. These improvements of healthcare infrastructure also boost the demand for new glioblastoma drugs which another factor responsible for the growth of global glioblastoma market from 2019 to 2027.
Global Glioblastoma Market: Regional Analysis
On geographical front, North America dominated the global glioblastoma market in 2018. The region is expected to continue its domination in the coming years of current tenure. This because of the presence and emergence several pharmaceutical companies devoted to the development of drugs to cure glioblastoma.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.